Cyclerion Therapeutics (NASDAQ:KRSA) Upgraded to “Strong-Buy” at UBS Group

UBS Group upgraded shares of Cyclerion Therapeutics (NASDAQ:KRSA) to a strong-buy rating in a report published on Thursday morning,Zacks reports.

Separately, Zacks Research raised Cyclerion Therapeutics to a “hold” rating in a research note on Wednesday. One research analyst has rated the stock with a Strong Buy rating and one has given a Hold rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus target price of $55.00.

Cyclerion Therapeutics Stock Up 29.9%

Shares of NASDAQ:KRSA opened at $31.91 on Thursday. The firm has a market capitalization of $21.38 million, a PE ratio of -2.75 and a beta of 1.75. Cyclerion Therapeutics has a 52 week low of $7.19 and a 52 week high of $59.36.

About Cyclerion Therapeutics

Cyclerion Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing medicines for serious diseases of the central nervous system. The company has concentrated on therapies designed to influence the nitric oxide–soluble guanylate cyclase signaling pathway, which may play a role in neurological and other debilitating conditions.

Cyclerion’s lead development program was IW-6463, an oral, central nervous system-penetrant soluble guanylate cyclase stimulator investigated for potential use in neurodegenerative diseases, including Alzheimer’s disease and amyotrophic lateral sclerosis.